Pre-exposure prophylaxis (PrEP) provides nearly 100% protection from HIV infection -- and it's also a powerful incentive to affirming primary care, as described by Demetre Daskalakis, M.D., M.P.H, and his patient Rubén Cabrera.
PrEP's success should not be measured by quantity but by quality. The basic level of health care accessibility should allow people high-quality health care provided by premiere providers and frontline staff.
It's time that patients, providers, pharmaceutical companies and the public health community have honest and difficult conversations about condoms, PrEP and bodily pleasure.
PrEP has been nothing short of revolutionary in changing the landscape of HIV prevention. What has been less discussed are the enormous secondary benefits that have followed the introduction of PrEP.
Critics have been warning since the concept of oral PrEP was in its infancy that it would lead to major increases in condomless sex among users and a corresponding dramatic spike in STIs. So far, the data has been inconclusive.
Could a provider's personal beliefs about condom use affect their willingness to prescribe PrEP? One study surveyed U.S. medical students and found bias in terms of willingness to offer PrEP based on clinical situations.
PrEP (pre-exposure prophylaxis) is highly effective at preventing HIV, but uptake has been slow around the world. We asked providers and community leaders what they thought needed to happen for PrEP to reach everybody who needs it.